Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBITDA (2021 - 2025)

Kiniksa Pharmaceuticals International's EBITDA history spans 5 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 259.03% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $59.1 million, up 236.39%, while the annual FY2025 figure was $59.1 million, 236.39% up from the prior year.
  • EBITDA reached $14.3 million in Q4 2025 per KNSA's latest filing, down from $18.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $224.1 million in Q3 2022 to a low of -$49.5 million in Q1 2021.
  • Average EBITDA over 5 years is $2.8 million, with a median of -$10.6 million recorded in 2023.
  • Peak YoY movement for EBITDA: skyrocketed 832.01% in 2022, then crashed 135.69% in 2024.
  • A 5-year view of EBITDA shows it stood at -$36.4 million in 2021, then skyrocketed by 112.58% to $4.6 million in 2022, then soared by 451.78% to $25.2 million in 2023, then plummeted by 135.69% to -$9.0 million in 2024, then skyrocketed by 259.03% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EBITDA are $14.3 million (Q4 2025), $18.3 million (Q3 2025), and $17.9 million (Q2 2025).